219 related articles for article (PubMed ID: 26662954)
1. Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan.
Weng WC; Huang YH; Yang SF; Wang SS; Kuo WH; Hsueh CW; Huang CH; Chou YE
Tumour Biol; 2016 May; 37(5):6971-7. PubMed ID: 26662954
[TBL] [Abstract][Full Text] [Related]
2. GSTO1*C/GSTO2*G haplotype is associated with risk of transitional cell carcinoma of urinary bladder.
Djukic T; Simic T; Radic T; Matic M; Pljesa-Ercegovac M; Suvakov S; Coric V; Pekmezovic T; Novakovic I; Dragicevic D; Savic-Radojevic A
Int Urol Nephrol; 2015 Apr; 47(4):625-30. PubMed ID: 25716313
[TBL] [Abstract][Full Text] [Related]
3. CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features.
Chou YE; Hsieh MJ; Chiou HL; Lee HL; Yang SF; Chen TY
Biomed Res Int; 2014; 2014():231474. PubMed ID: 24971320
[TBL] [Abstract][Full Text] [Related]
4. CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan.
Chou YE; Hsieh MJ; Hsin CH; Chiang WL; Lai YC; Lee YH; Huang SC; Yang SF; Lin CW
PLoS One; 2014; 9(4):e93692. PubMed ID: 24699672
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer.
Wang L; Habuchi T; Takahashi T; Mitsumori K; Kamoto T; Kakehi Y; Kakinuma H; Sato K; Nakamura A; Ogawa O; Kato T
Carcinogenesis; 2002 Feb; 23(2):257-64. PubMed ID: 11872630
[TBL] [Abstract][Full Text] [Related]
6. Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis.
Liu Y; Qing H; Su X; Wang C; Li Z; Liu S
Med Sci Monit; 2015 Sep; 21():2694-700. PubMed ID: 26356590
[TBL] [Abstract][Full Text] [Related]
7. DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder.
Ma X; Xu H; Zheng T; Li HZ; Shi TP; Wang BJ; Ju ZH; Wang C; Zhang GX; Zhang X
BJU Int; 2008 Aug; 102(5):633-6. PubMed ID: 18384629
[TBL] [Abstract][Full Text] [Related]
8. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
[TBL] [Abstract][Full Text] [Related]
9. HLA-G polymorphism and transitional cell carcinoma of the bladder in a Brazilian population.
Castelli EC; Mendes-Junior CT; Viana de Camargo JL; Donadi EA
Tissue Antigens; 2008 Aug; 72(2):149-57. PubMed ID: 18721275
[TBL] [Abstract][Full Text] [Related]
10. Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer.
Liao CH; Chang WS; Tsai CW; Hu PS; Wu HC; Hsu SW; Chen GL; Yueh TC; Shen TC; Hsia TC; Bau DT
In Vivo; 2018; 32(5):1045-1050. PubMed ID: 30388078
[TBL] [Abstract][Full Text] [Related]
11. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder.
Vázquez-Lavista LG; Lima G; Gabilondo F; Llorente L
Urology; 2009 Aug; 74(2):414-8. PubMed ID: 19646633
[TBL] [Abstract][Full Text] [Related]
12. SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan.
Hsu LI; Chiu AW; Huan SK; Chen CL; Wang YH; Hsieh FI; Chou WL; Wang LH; Chen CJ
Toxicol Appl Pharmacol; 2008 Apr; 228(2):144-55. PubMed ID: 18199464
[TBL] [Abstract][Full Text] [Related]
13. The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene.
Safarinejad MR; Shafiei N; Safarinejad SH
Arch Toxicol; 2011 Oct; 85(10):1209-18. PubMed ID: 21347663
[TBL] [Abstract][Full Text] [Related]
14. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
[TBL] [Abstract][Full Text] [Related]
15. Effect of
Hung SC; Wang SS; Li JR; Chen CS; Yang CK; Chiu KY; Cheng CL; Ou YC; Ho HC; Yang SF
Int J Med Sci; 2018; 15(14):1731-1736. PubMed ID: 30588197
[TBL] [Abstract][Full Text] [Related]
16. DNA repair gene XRCC1 polymorphisms and bladder cancer risk.
Sak SC; Barrett JH; Paul AB; Bishop DT; Kiltie AE
BMC Genet; 2007 Apr; 8():13. PubMed ID: 17425776
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer.
Zhou B; Zhang P; Tang T; Liao H; Zhang K; Pu Y; Chen P; Song Y; Zhang L
BMC Cancer; 2015 May; 15():433. PubMed ID: 26014498
[TBL] [Abstract][Full Text] [Related]
18. A functional variant rs1464938 in the promoter of fibroblast growth factor 12 is associated with an increased risk of bladder transitional cell carcinoma.
Wu J; Huang H; Huang Q; Qiu R; Huang M; Meng D
Cytokine; 2020 Dec; 136():155294. PubMed ID: 32950810
[TBL] [Abstract][Full Text] [Related]
19. WISP1 genetic variants as predictors of tumor development with urothelial cell carcinoma.
Lee HL; Chiou HL; Wang SS; Hung SC; Chou MC; Yang SF; Hsieh MJ; Chou YE
Urol Oncol; 2018 Apr; 36(4):160.e15-160.e21. PubMed ID: 29277583
[TBL] [Abstract][Full Text] [Related]
20. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
